Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Julie Gottlieb Fisher, David L. Tait, Elizabeth Garrett‐Mayer, Susan Halabi, Pam K. Mangat, Julian C. Schink, Ricardo H. Álvarez, Dan S. Veljovich, Timothy Lewis Cannon, Pamela Crilley, Theodore Pollock, Carmen Calfa, Tareq Al Baghdadi, Ramya Thota, Nicole D. Fleming, Jared Addison Cotta, Andrew L. Rygiel, Sasha L. Warren, Richard L. Schilsky